

Prior authorization requirements for Cabazitaxel (Jevtana)

Effective September 1, 2018, prior authorization (PA) requirements will change for injectable drug Cabazitaxel (Jevtana) to be covered by Amerigroup District of Columbia, Inc. Federal and district law, as well as district contract language and Centers for Medicare & Medicaid Services guidelines, including definitions and specific contract provisions/exclusions take precedence over these PA rules and must be considered first when determining coverage. **Noncompliance with new requirements may result in denied claims.**

PA requirements will be added to the following:

- Cabazitaxel (Jevtana) — injection, 1 mg (J9043)

To request PA, you may use one of the following methods:

- **Web:** <https://www.availity.com>
- **Fax:** 1-800-964-3627
- **Phone:** 1-800-454-3730

Not all PA requirements are listed here. Detailed PA requirements are available to contracted providers on the provider website (<https://providers.amerigroup.com/DC> > Quick Tools > [Precertification Lookup Tool](#)). Additionally, providers may call us at 1-800-454-3730 for PA requirements.